Author: admin

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Lucio Crino? discusses extreme rare mutations in lung cancer (ROS1, TRK, HER2) and the treatment opportunities available for them. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Nicholas Girard discusses the mechanisms of resistance to EGFR TKIs and new treatment strategies for combating this resistance. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Guilio Rossi discusses the an algorithm for molecular testing of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. John Gosney discusses the inherent challenges faced by the pathologist in the era of personalized medicine. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Joachim G. Aerts discusses response criteria and kinetics with the use of immunocheckpoint inhibitors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Joachim G. Aerts discusses how biomarkers predict the clinical activity of immunocheckpoints. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. David Waller argues that surgery is the treatment of choice for Stage 1 non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Umberto Ricardi argues that steretactic body radiation therapy (SBRT) is the treatment of choice for Stage 1 non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. John Vansteenkiste discusses the current status of adjuvant thereapy for the treatment of non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Richard Booton discusses the use of endobronchial and other techniquces to opmize the diagnosis and treatment of lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Pieter E. Postmus discusses new proposals for a new TNM classification for lung cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Klaus Irion discusses the use of diagnotics for the staging of lung cancer including the use of functional imaging and volumetric assessment. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7211 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. John P. Leonard argues that watch and wait may still be utilized in cases of follicular lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Michael E. Williams argues that “watch and wait” should not be utilized in the treatment of follicular lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Andrew M. Evens discusses the latest in the initial management of Hodgkin lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Morton Coleman argues that one should not utilize surveillance imagine for diffuse large b-cell lymphoma (DLBCL) patients in remission. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Michell R. Smith argues that we should utilze surveillance imaging for diffuce large b-cell lymphoma (DLBCL) patients who are in remission. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Tracy Batchelor discusses the latest updates in primary CNS lymphoma management. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jonathan Friedberg argues that young paitnts with mantle cell lymphoma (MCL) should not be treated aggressively. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Brad S. Kahl argues that young patients with mantle cell lymphoma (MCL) should be treated aggressively. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Anas Younas discusses immune checkpoint inhibitors in lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Richard I. Fisher argues that R-CHOP should be utilized to treat patients with ABC-type diffuce large b-cell lymphoma (DLBCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Pierluigi Porcu argues that allogeneic stem cell transplant is the best approach for relapsed T cell lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Rafael Bejar discusses the promises and pitfalls in using molecular testing in the diagnosis of myelodysplastic syndromes (MDS). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Selina M. Luger argues that hypomethylating agents should be used with caution in lower-risk patients with myelodysplastic syndromes (MDS). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Eric Padron discusses the management of chronic myelomonocytic leukemia (CMML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben A. Mesa discusses combination therapy with JAK2 inhibitors in the treatment of myeloproliferative neoplasms (MPN). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Sarah Nikiforow discusses the diagnosis and management of hemophagocytic lymphohistiocytosis (HLH). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Kenneth A. Bauer discusses the reversal of newer anticoagulants. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Eric Padron discusses the diagnosis and management of atypical chronic myelogenous leukemia (CML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jerald P. Racdich discusses practical advices for the molecular monitoring of chronic myelogenous leukemia (CML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jerald P. Radich discusses at what point tyrosine kinase inhibitors can be stopped in the treatment of chronic myelogenous leukemia (CML). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul Barr argues that the optimal treatment for chronic lymphocytic leukemia (CLL) patients with a 17p deletion is the use of a novel agent. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jacqueline Barrientos argues that ibrutinib is the optimal treatment for chronic lymphocytic leukemia (CLL) patiens with a 17p deletion. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Timothy Call discusses the clinical considerations for the use of oral targeted therapies in chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Richard R. Furman argues that CR and MRD negativity is no longer required for treatment of CLL in the era of novel agents. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Robert Z. Orlowski argues that the best multiple myeloma salvage therapy is KRD. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that the best multiple myeloma salvage therapy is novel therapy. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that upfront transplant should no longer be considered a standard of care in the treatment of myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben Niesvizky argues that high risk myeloma should not be treated differently. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Robert Z. Orlowski argues that high risk myeloma should be treated differently. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that the standard induction regimen for myeloma is RVD. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben Niesvizky discusses the use of monoclonal antibodies for the treatment of multiple myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Josep Tabernero discusses novel approaches to trial design in the era of molecular subtyping. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Karen T. Brown argues that ablation is the optimal treatment of localized hepatocellular carcinoma (HCC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael A. Choti argues that the optimal treatment of localized hepatocellular carcinoma (HCC) is either resection or transplant. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that FOLFIRINOX is the optimal chemotherapy backbone for targeted agents in pancreatic cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that FOLFIRINOX is the optimal chemotherapy backbone for targeted agents in pancreatic cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael A. Choti argues that chemotherapy alone is the preferred treatment for borderline, resectable pancreatic cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Jeffrey A. Meyerhardt argues that epirubicin and other anthracyclines still have a role to play in the treatment of GI cancers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.